Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Mar 6, 2017
CAMBRIDGE, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Howard Mayer, M.D., senior vice president and head of global clinical development at Shire plc, has joined its board of directors. Genocea also anno...
Mar 1, 2017
CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Jonathan Poole, chief financial officer, will present a company overview at the upcoming Cowen and Company 37th Annual Health Care Conference on Wed...
Feb 16, 2017
- Positive Phase 2b clinical data confirm attractive profile for GEN-003; expected to start Phase 3 program in 4Q 2017 - - Neoantigen cancer vaccine program on track to file first IND by end of 2017- - Conference call at 9am ET today - CAMBRIDGE, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmac...
Feb 9, 2017
CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, February 16, 2017 at 9:00 a.m. ET to discuss financial results for the fourth quar...
Jan 5, 2017
- Trial meets statistical significance vs. placebo for multiple clinical endpoints through six months - - End of Phase 2 meeting with FDA expected in Q1 2017 - - Phase 3 launch expected in Q4 2017 - - GEN-003 has potential to be first new treatment for genital herpes infections in more than 20 years - - Company to host conference cal...
Dec 14, 2016
- GEN-003 Phase 2b placebo-controlled clinical efficacy data six months after dosing expected in January 2017 - - Announced new research collaborations with Checkmate Pharmaceuticals in advancedmelanoma and US Oncology Research across multiple cancers - - Neoantigen cancer vaccine IND expected in 2017 - CAMBRIDGE, Mass., Dec. 14, 2016...
Dec 14, 2016
- Genocea's ATLAS technology to profile the T cell responses of patients enrolled in ongoing Phase 1b CMP-001/pembrolizumab clinical trial against library of common melanoma antigens - - Collaboration aims to identify antigens associated with therapeutic T cell responses - CAMBRIDGE, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Genocea Bio...
Dec 8, 2016
CAMBRIDGE, Mass., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, will host a virtual Research and Development (R&D) Day for analysts, investors and media on Wednesday, December 14, 2016, starting at 8:30 a.m. ET. This event will be ava...
Nov 11, 2016
- ATLAS discovers neoantigens, through functional T cell responses, which were not identified by predictive algorithms - - Majority of antigens predicted by algorithms not biologically relevant in ATLAS assays - - Data to be presented at 2016 SITC Annual Meeting - CAMBRIDGE, Mass., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, In...
Nov 9, 2016
CAMBRIDGE, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at two upcoming investor conferences in November: Stifel 2016 Healthcare Conference: Corporate presen...
Nov 3, 2016
- Positive Phase 2b results recently reported and dose selected for GEN-003 Phase 3 program expected to initiate in 2H 2017 - - Conference Call at 9am ET today - CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today reported corp...
Oct 28, 2016
- Increase in CD4+ polyfunctional T cells indicates GEN-003 is stimulating a multi-faceted T cell immune response to genital herpes - - GEN-003 elicited strong antibody responses at 12 months post-dosing - CAMBRIDGE, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vacci...
Oct 27, 2016
CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, November 3, 2016 at 9:00 a.m. ET to discuss financial results for the third quarte...
Sep 29, 2016
- Trial achieves primary endpoint - - Dose confirmed for subsequent trials -   - Phase 3 expected to start in 2H 2017 - - Company to host conference call at 9 a.m. ET today - CAMBRIDGE, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immu...
Aug 9, 2016
CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, is delighted to congratulate Jessica Baker Flechtner, Ph.D., chief scientific officer, who was acknowledged as an honoree on this year's 40 Women to Watch Over 40 list. T...
= add release to Briefcase